Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LQDA

Liquidia Corp

Jun 10 • 04:00PM ET

65.25

+1.24 1.94 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • Mid • NASD

Peers: AMRX BHC ALKS INDV LNTH KNSA VTRS TEVA BMRN TLX

| Held by: IWM VTI IWO VXF SCHA FESM KOMP VTWO IWC IHE

Index	RUT	P/E	460.81	EPS (ttm)	0.14	Insider Own	17.93%	Shs Outstand	88.31M	Perf Week	17.17%
Market Cap	5.80B	Forward P/E	11.46	EPS next Y	5.70	Insider Trans	-12.37%	Shs Float	72.98M	Perf Month	22.81%
Enterprise Value	5.76B	PEG	-	EPS next Q	0.79	Inst Own	67.28%	Short Float	13.64%	Perf Quarter	69.22%
Income	22.30M	P/S	20.14	EPS this Y	518.56%	Inst Trans	-1.39%	Short Ratio	7.01	Perf Half Y	86.38%
Sales	288.06M	P/B	53.07	EPS next Y	70.10%	ROA	7.09%	Short Interest	9.96M	Perf YTD	89.19%
Book/sh	1.23	P/C	26.04	EPS next 5Y	-	ROE	28.18%	52W High	66.78 -2.28%	Perf Year	335.58%
Cash/sh	2.51	P/FCF	141.01	EPS past 3/5Y	-5.98% 14.60%	ROIC	9.20%	52W Low	11.85 450.63%	Perf 3Y	675.86%
Dividend Est.	-	EV/EBITDA	122.31	Sales past 3/5Y	114.98% 192.49%	Gross Margin	91.51%	Volatility	9.55% 6.68%	Perf 5Y	2272.73%
Dividend TTM	-	EV/Sales	20.01	EPS Y/Y TTM	115.40%	Oper. Margin	15.81%	ATR (14)	3.87	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.03	Sales Y/Y TTM	1936.66%	Profit Margin	7.74%	RSI (14)	69.95	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.22	EPS Q/Q	216.05%	SMA20	7.98%	Beta	0.60	Target Price	67.14
Payout	-	Debt/Eq	1.70	Sales Q/Q	4158.49%	SMA50	35.75%	Rel Volume	1.64	Prev Close	64.01
Employees	216	LT Debt/Eq	1.23	Earnings	May 11 BMO	SMA200	83.21%	Avg Volume	1.42M	Price	65.25
IPO	Jul 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.77% 11.24%	Trades		Volume	2,328,018	Change	1.94%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$31
Aug-15-25	Resumed	Jefferies	Buy	$43
May-19-25	Downgrade	Oppenheimer	Perform → Underperform	$13
Dec-20-24	Initiated	Wells Fargo	Overweight	$20
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform	$27
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

Jun-08-26 08:30AM	Liquidia Corporation Announces Inclusion in the S&P SmallCap 600 Index (GlobeNewswire)
Jun-05-26 07:25PM	Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
May-27-26 08:30AM	Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 03:03AM	Liquidia Corp (LQDA) Q1 2026 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) +6.53%
May-11-26 04:56PM	Liquidia Corporation Q1 2026 Earnings Call Summary (Moby) +25.60%
10:10AM	Loading…
10:10AM	Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat (InvestorsHub)
06:30AM	Liquidia Corporation Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 08:30AM	Liquidia Corporation to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.01%
May-04-26 08:30AM	Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026 (GlobeNewswire)
Apr-07-26 08:00AM	Liquidia Corporation to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-03-26 08:00PM	Does Liquidia Corporation (LQDA) Have the Potential to Rally 34.47% as Wall Street Analysts Expect? (Quartz)
Mar-10-26 10:00AM	Best Momentum Stocks to Buy for March 10th (Zacks) +8.25%
Mar-05-26 10:10PM	Liquidia Q4 Earnings Call Highlights (MarketBeat)
04:02PM	Liquidia Corp (LQDA) Q4 2025 Earnings Call Highlights: Record Sales Surge and Strategic Growth (GuruFocus.com)
08:30AM	Liquidia Corporation Q4 2025 Earnings Call Summary (Moby)
07:45AM	Loading…
07:45AM	Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 12:15PM	Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026 (GlobeNewswire)
Feb-16-26 11:07AM	Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling (Insider Monkey)
Feb-12-26 11:40AM	EXEL or LQDA: Which Is the Better Value Stock Right Now? (Zacks)
Jan-27-26 08:30AM	Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress (GlobeNewswire)
Jan-16-26 08:29AM	Laughing Water Capital's Updates on Liquidia Corp (LQDA) (Insider Monkey)
Jan-15-26 12:00PM	Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-09-26 07:09PM	Why Liquidia Stock Rocked the Market Today (Motley Fool) +12.91%
06:30AM	Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update (GlobeNewswire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
Jan-07-26 07:00AM	Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 09:06AM	Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus (Zacks)
Dec-11-25 09:22AM	Arquitos Capital Management's Updates on Liquidia Corporation (LQDA) (Insider Monkey)
09:55AM	Loading…
Nov-24-25 09:55AM	Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
Nov-16-25 10:14PM	Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA's 75% Growth in U.S. Prostacyclin Revenue (Insider Monkey)
Nov-06-25 09:55AM	Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet (Zacks)
Nov-05-25 06:39AM	Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment (Insider Monkey) -5.34%
Nov-03-25 04:02PM	Liquidia Corp (LQDA) Q3 2025 Earnings Call Highlights: Strong YUTREPIA Sales Drive Positive ... (GuruFocus.com) +10.67%
08:00AM	Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences (GlobeNewswire)
06:30AM	Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 09:21AM	Liquidia Corp (LQDA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
Oct-28-25 10:00AM	Niagen Bioscience (NAGE) Reports Next Week: What to Expect (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 08:30AM	Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-21-25 09:55AM	Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade (Zacks)
Oct-16-25 04:33PM	BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating (Insider Monkey)
Oct-07-25 06:30AM	Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 (GlobeNewswire) +5.10%
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
Sep-29-25 08:30AM	Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting (GlobeNewswire)
Sep-24-25 04:06AM	Liquidia Corporation (LQDA) Presents Strategic Overview at Well Fargo's Annual Healthcare Conference 2025 (Insider Monkey)
Sep-23-25 10:32AM	Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares? (Insider Monkey)
Sep-16-25 02:15PM	Liquidia Corporation (LQDA): A Bull Case Theory (Insider Monkey)
Sep-11-25 08:30AM	Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium (GlobeNewswire)
Sep-04-25 01:14PM	Jefferies Highlights Yutrepia's Market Edge in Supporting a Buy on Liquidia (LQDA) (Insider Monkey)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
Sep-01-25 01:04AM	BTIG Raises Price Target for Liquidia (LQDA), Keeps Buy Rating (Insider Monkey)
Aug-27-25 08:30AM	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-18-25 11:40PM	Court Victory and Fresh Funding Propel Growth at Liquidia Corporation (Insider Monkey) +6.82%
Aug-13-25 12:54PM	Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge (Insider Monkey)
03:08AM	Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YUTREPIA Launch and Financial Position (GuruFocus.com)
Aug-12-25 04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily) +13.68%
03:00PM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
06:30AM	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:22AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q2 2025 Result (GuruFocus.com)
Aug-05-25 08:30AM	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily) +5.75%
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jun-23-25 04:34PM	Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA (GlobeNewswire)
Jun-11-25 11:04AM	Insmed Stock Jumps 29% on Encouraging PAH Study Results (Zacks) -5.67%
Jun-10-25 04:07PM	Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia (Investor's Business Daily) -16.87%
Jun-02-25 06:30AM	Liquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD (GlobeNewswire) +13.07%
May-28-25 08:00AM	Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -9.13%
May-24-25 10:47AM	FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute (Insider Monkey)
May-23-25 02:28PM	U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (GlobeNewswire)
May-12-25 06:00AM	Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics (GlobeNewswire)
May-09-25 03:21AM	Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... (GuruFocus.com)
May-08-25 11:06AM	Buckley Capital's Views on Liquidia Corp. (LQDA) (Insider Monkey)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 06:35PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
11:16AM	Liquidia Q1 2025 Earnings Preview (Seeking Alpha)
10:15AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q1 2025 Result (GuruFocus.com)
May-06-25 08:00AM	Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
09:50AM	Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains? (Zacks)
May-02-25 05:28PM	District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia (GlobeNewswire) +13.23%
May-01-25 08:00AM	Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-30-25 09:30AM	Arquitos Capital's Largest Holdings For Q1 2025 (Seeking Alpha)
Apr-29-25 07:40AM	Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates (Zacks) -5.06%
05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-25-25 06:30AM	Arquitos Capital Management Q1 2025 Investor Letter (Seeking Alpha)
Apr-07-25 06:38AM	Liquidia: United Therapeutics Has The Last Laugh (Seeking Alpha)
Apr-01-25 10:33AM	UPDATE Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00AM	Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

CEO & DirectorDr. Roger A. Jeffs Ph.D.

COO & CFOMr. Michael Kaseta

General Counsel & Corporate SecretaryMr. Russell Schundler

Chief Commercial OfficerMr. Scott Moomaw

Chief Medical OfficerDr. Rajeev Saggar M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Canaan VIII LP	Director	Jun 10 '26	Proposed Sale	65.00	200,000	13,000,000		Jun 10 04:52 PM
Khindri Sanjeev	Chief Development Officer	Jun 08 '26	Sale	65.46	4,134	270,612	67,132	Jun 10 04:31 PM
Bloch Stephen M	Director	Jun 08 '26	Sale	64.76	148,301	9,603,989	1,636,941	Jun 10 04:30 PM
Bloch Stephen M	Director	Jun 09 '26	Sale	64.38	72,534	4,669,693	1,564,407	Jun 10 04:30 PM
Manning Paul B	Director	Jun 04 '26	Sale	63.91	200,000	12,782,059	716,311	Jun 08 04:41 PM
Bloch Stephen M	Director	Jun 04 '26	Sale	64.97	82,736	5,375,398	1,787,306	Jun 08 04:30 PM
Bloch Stephen M	Director	Jun 05 '26	Sale	64.14	2,064	132,384	1,785,242	Jun 08 04:30 PM
Canaan VIII LP	Director	Jun 08 '26	Proposed Sale	64.00	200,000	12,800,000		Jun 08 04:11 PM
Paul B Manning	Director	Jun 04 '26	Proposed Sale	55.69	200,000	11,138,000		Jun 04 06:38 PM
Canaan VIII LP	Director	Jun 04 '26	Proposed Sale	65.00	200,000	13,000,000		Jun 04 05:24 PM
Krepp Sarah	Chief Human Resource Officer	Jun 01 '26	Sale	60.87	276	16,800	146,743	Jun 03 04:31 PM
KIRSCH ARTHUR S	Director	Jun 01 '26	Sale	60.22	15,000	903,300	15,000	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 03 '26	Sale	54.80	10,000	548,000	0	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 02 '26	Sale	56.00	5,000	280,000	10,000	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 01 '26	Proposed Sale	61.37	30,000	1,841,100		Jun 01 09:56 AM
JEFFS ROGER	Chief Executive Officer	May 27 '26	Sale	62.18	6,428	399,712	1,041,667	May 28 04:30 PM
SINGH RAMAN	Director	May 21 '26	Option Exercise	9.44	29,494	278,352	68,249	May 26 06:17 PM
SINGH RAMAN	Director	May 21 '26	Sale	60.13	29,494	1,773,436	38,755	May 26 06:17 PM
JEFFS ROGER	Chief Executive Officer	May 22 '26	Sale	61.52	25,000	1,538,055	1,073,095	May 26 06:16 PM
JEFFS ROGER	Chief Executive Officer	May 21 '26	Sale	61.13	25,000	1,528,160	1,098,095	May 26 06:16 PM
JEFFS ROGER	Chief Executive Officer	May 26 '26	Sale	60.38	25,000	1,509,460	1,048,095	May 26 06:16 PM
RAMANDEEP SINGH	Director	May 21 '26	Proposed Sale	60.13	29,494	1,773,437		May 21 05:12 PM
Caligan Partners LP	Director	May 19 '26	Buy	59.98	5,300	317,894	8,138,951	May 20 08:51 PM
Caligan Partners LP	Director	May 19 '26	Sale	59.98	5,300	317,894	8,133,651	May 20 08:51 PM
JEFFS ROGER	Chief Executive Officer	May 20 '26	Sale	61.30	25,000	1,532,548	1,123,095	May 20 06:55 PM
JEFFS ROGER	Chief Executive Officer	May 19 '26	Sale	58.65	25,000	1,466,142	1,148,095	May 20 06:55 PM
JEFFS ROGER	Chief Executive Officer	May 18 '26	Sale	56.77	25,000	1,419,320	1,173,095	May 20 06:55 PM
SERENDIPITY BIOPHARMA LLC	Director	May 20 '26	Proposed Sale	59.98	106,428	6,383,551		May 20 04:37 PM
JEFFS ROGER	Chief Executive Officer	May 14 '26	Sale	58.62	25,000	1,465,565	1,223,095	May 15 06:59 PM
JEFFS ROGER	Chief Executive Officer	May 15 '26	Sale	57.04	25,000	1,426,072	1,198,095	May 15 06:59 PM
JEFFS ROGER	Chief Executive Officer	May 13 '26	Sale	56.29	25,000	1,407,128	1,248,095	May 15 06:59 PM
SERENDIPITY BIOPHARMA LLC	Director	May 14 '26	Proposed Sale	57.59	100,000	5,759,000		May 14 04:26 PM
Bloch Stephen M	Director	May 11 '26	Sale	50.23	318,893	16,016,775	1,870,042	May 13 04:30 PM
JEFFS ROGER	Chief Executive Officer	May 12 '26	Sale	54.04	25,000	1,350,990	1,273,095	May 12 06:52 PM
JEFFS ROGER	Chief Executive Officer	May 08 '26	Sale	42.14	25,000	1,053,565	1,323,095	May 12 06:52 PM
JEFFS ROGER	Chief Executive Officer	May 11 '26	Sale	41.50	25,000	1,037,402	1,298,095	May 12 06:52 PM
Canaan VIII LP	Director	May 11 '26	Proposed Sale	49.86	318,893	15,900,000		May 11 05:52 PM
SERENDIPITY BIOPHARMA LLC	Director	May 08 '26	Proposed Sale	42.28	100,000	4,228,000		May 08 04:19 PM
JEFFS ROGER	Chief Executive Officer	May 07 '26	Sale	42.09	25,000	1,052,135	1,348,095	May 07 06:19 PM
JEFFS ROGER	Chief Executive Officer	May 06 '26	Sale	40.78	25,000	1,019,572	1,373,095	May 07 06:19 PM
JEFFS ROGER	Chief Executive Officer	May 05 '26	Sale	40.10	25,000	1,002,593	1,398,095	May 07 06:19 PM
SERENDIPITY BIOPHARMA LLC	Director	May 07 '26	Proposed Sale	42.14	25,000	1,053,500		May 07 04:18 PM
Boyle Dana	Chief Accounting Officer	Apr 27 '26	Sale	37.78	1,576	59,541	175,342	Apr 29 04:31 PM
Adair Jason	Chief Business Officer	Apr 27 '26	Sale	41.65	688	28,655	214,738	Apr 29 04:30 PM
JEFFS ROGER	Chief Executive Officer	Apr 17 '26	Sale	40.60	18,839	764,956	1,423,095	Apr 21 04:30 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 17 '26	Proposed Sale	41.40	68,839	2,849,935		Apr 17 04:39 PM
JEFFS ROGER	Chief Executive Officer	Apr 16 '26	Sale	40.31	25,000	1,007,800	1,441,934	Apr 16 08:38 PM
JEFFS ROGER	Chief Executive Officer	Apr 15 '26	Sale	40.14	25,000	1,003,522	1,466,934	Apr 16 08:38 PM
JEFFS ROGER	Chief Executive Officer	Apr 14 '26	Sale	40.00	3,300	132,000	1,491,934	Apr 16 08:38 PM
Kaseta Michael	CFO and COO	Apr 15 '26	Option Exercise	2.79	86,971	242,649	483,702	Apr 16 08:37 PM
Kaseta Michael	CFO and COO	Apr 14 '26	Option Exercise	2.79	3,000	8,370	408,775	Apr 16 08:37 PM
Kaseta Michael	CFO and COO	Apr 15 '26	Sale	40.14	139,390	5,595,240	353,356	Apr 16 08:37 PM
Kaseta Michael	CFO and COO	Apr 14 '26	Sale	40.00	3,000	120,000	405,775	Apr 16 08:37 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 16 '26	Proposed Sale	40.12	25,000	1,003,000		Apr 16 04:13 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 15 '26	Proposed Sale	38.71	24,733	957,414		Apr 15 04:43 PM
MICHAEL KASETA	Officer	Apr 15 '26	Proposed Sale	38.71	139,390	5,395,787		Apr 15 04:42 PM
Moomaw Scott	Chief Commercial Officer	Apr 13 '26	Sale	38.34	10,547	404,402	184,558	Apr 14 05:08 PM
Adair Jason	Chief Business Officer	Apr 13 '26	Sale	38.37	7,301	280,139	215,426	Apr 14 05:07 PM
Boyle Dana	Chief Accounting Officer	Apr 13 '26	Sale	38.37	5,101	195,725	176,918	Apr 14 05:07 PM
Kaseta Michael	CFO and COO	Apr 10 '26	Option Exercise	2.79	23,821	66,461	435,676	Apr 14 05:07 PM
Kaseta Michael	CFO and COO	Apr 10 '26	Sale	40.14	23,821	956,249	411,855	Apr 14 05:07 PM
Kaseta Michael	CFO and COO	Apr 13 '26	Sale	38.37	18,958	727,418	405,775	Apr 14 05:07 PM
Krepp Sarah	Chief Human Resource Officer	Apr 13 '26	Sale	38.37	4,557	174,852	147,019	Apr 14 05:06 PM
Saggar Rajeev	Chief Medical Officer	Apr 13 '26	Sale	38.37	9,220	353,771	173,270	Apr 14 05:06 PM
Schundler Russell	General Counsel	Apr 13 '26	Sale	38.37	13,692	525,362	610,532	Apr 14 05:05 PM
JEFFS ROGER	Chief Executive Officer	Apr 13 '26	Sale	38.37	32,744	1,256,387	1,137,599	Apr 14 05:05 PM
JEFFS ROGER	Chief Executive Officer	Apr 10 '26	Sale	40.12	21,433	859,877	1,495,234	Apr 14 05:05 PM
MICHAEL KASETA	Officer	Apr 14 '26	Proposed Sale	38.85	3,000	116,550		Apr 14 04:37 PM
JEFFS ROGER	Chief Executive Officer	Apr 09 '26	Sale	40.12	25,000	1,002,887	1,516,667	Apr 13 05:47 PM
Kaseta Michael	CFO and COO	Apr 09 '26	Option Exercise	2.80	133,789	374,032	545,644	Apr 13 05:47 PM
Kaseta Michael	CFO and COO	Apr 09 '26	Sale	40.24	133,789	5,383,388	411,855	Apr 13 05:47 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 10 '26	Proposed Sale	40.32	25,000	1,008,000		Apr 10 04:35 PM
MICHAEL KASETA	Officer	Apr 10 '26	Proposed Sale	40.32	23,821	960,463		Apr 10 04:34 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 09 '26	Proposed Sale	38.19	25,000	954,750		Apr 09 04:22 PM
MICHAEL KASETA	Officer	Apr 09 '26	Proposed Sale	38.19	133,789	5,109,402		Apr 09 04:21 PM
Bloch Stephen M	Director	Mar 27 '26	Sale	35.94	62,550	2,247,780	2,188,935	Mar 30 05:43 PM
Bloch Stephen M	Director	Mar 26 '26	Sale	37.22	7,684	285,985	2,251,485	Mar 30 05:43 PM
Canaan VIII LP	Board Member	Mar 27 '26	Proposed Sale	33.57	62,550	2,100,000		Mar 27 04:27 PM
Canaan VIII LP	Board Member	Mar 26 '26	Proposed Sale	37.09	7,684	285,000		Mar 26 04:21 PM
Moomaw Scott	Chief Commercial Officer	Mar 23 '26	Option Exercise	3.40	17,000	57,800	204,640	Mar 25 04:30 PM
Moomaw Scott	Chief Commercial Officer	Mar 23 '26	Sale	36.79	18,314	673,752	187,640	Mar 25 04:30 PM
Saggar Rajeev	Chief Medical Officer	Mar 13 '26	Sale	36.30	35,365	1,283,834	174,473	Mar 17 04:31 PM
Krepp Sarah	Chief Human Resource Officer	Mar 13 '26	Sale	38.00	16,261	617,918	148,397	Mar 17 04:30 PM
SINGH RAMAN	Director	Mar 13 '26	Option Exercise	4.86	20,000	97,200	58,755	Mar 17 04:30 PM
SINGH RAMAN	Director	Mar 13 '26	Sale	36.04	20,000	720,828	38,755	Mar 17 04:30 PM
RAMANDEEP SINGH	Director	Mar 13 '26	Proposed Sale	36.11	40,359	1,457,296		Mar 13 04:46 PM
Rajeev Saggar	Officer	Mar 13 '26	Proposed Sale	36.30	35,365	1,283,834		Mar 13 04:37 PM
SARAH T KREPP	Officer	Mar 13 '26	Proposed Sale	38.00	16,261	617,918		Mar 13 04:05 PM
Moomaw Scott	Chief Commercial Officer	Mar 09 '26	Option Exercise	3.21	80,000	256,821	268,954	Mar 11 04:30 PM
Moomaw Scott	Chief Commercial Officer	Mar 09 '26	Sale	35.32	80,000	2,825,824	188,954	Mar 11 04:30 PM
SCOTT MOOMAW	Officer	Mar 09 '26	Proposed Sale	36.03	100,000	3,603,000		Mar 09 04:37 PM
Schundler Russell	General Counsel	Mar 02 '26	Sale	30.58	1,073	32,812	614,057	Mar 03 04:34 PM
Moomaw Scott	Chief Commercial Officer	Mar 02 '26	Sale	30.58	827	25,290	188,954	Mar 03 04:33 PM
Krepp Sarah	Chief Human Resource Officer	Mar 02 '26	Sale	30.58	276	8,440	164,658	Mar 03 04:32 PM
Kaseta Michael	CFO and COO	Mar 02 '26	Sale	30.58	1,165	35,626	411,855	Mar 03 04:31 PM
Boyle Dana	Chief Accounting Officer	Mar 02 '26	Sale	30.58	445	13,608	178,840	Mar 03 04:30 PM
Adair Jason	Chief Business Officer	Mar 02 '26	Sale	30.58	689	21,070	212,479	Mar 03 04:30 PM
Boyle Dana	Chief Accounting Officer	Jan 26 '26	Sale	41.65	1,580	65,807	178,848	Jan 28 04:30 PM
Adair Jason	Chief Business Officer	Jan 26 '26	Sale	41.65	688	28,655	211,169	Jan 28 04:30 PM
Krepp Sarah	Chief Human Resource Officer	Jan 12 '26	Sale	37.43	13,165	492,766	140,769	Jan 13 04:36 PM

Open in Screener

CADL

Candel Therapeutics Inc

Jun 10 • 04:00PM ET

8.35

-0.32 -3.69 %

Healthcare • Biotechnology • USA • Small • NASD

CADL Candel Therapeutics Inc daily Stock Chart

Peers: CGON IDYA RCUS TNGX NUVL BMRN INCY KYMR RYTM KRYS

| Held by: VTI IWM IBB IWO VXF VTWO ITOT IWC SBIO IWN

Index	RUT	P/E	-	EPS (ttm)	-0.98	Insider Own	20.98%	Shs Outstand	73.26M	Perf Week	-5.11%
Market Cap	611.80M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	3.71%	Shs Float	57.90M	Perf Month	-5.65%
Enterprise Value	466.24M	PEG	-	EPS next Q	-0.24	Inst Own	54.63%	Short Float	24.46%	Perf Quarter	63.73%
Income	-54.42M	P/S	-	EPS this Y	-30.37%	Inst Trans	25.98%	Short Ratio	7.89	Perf Half Y	53.21%
Sales	0.00M	P/B	4.43	EPS next Y	28.85%	ROA	-36.55%	Short Interest	14.16M	Perf YTD	47.79%
Book/sh	1.88	P/C	3.14	EPS next 5Y	-	ROE	-51.17%	52W High	9.57 -12.75%	Perf Year	42.74%
Cash/sh	2.66	P/FCF	-	EPS past 3/5Y	-3.41% -3.52%	ROIC	-29.13%	52W Low	4.35 91.95%	Perf 3Y	468.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.78% 7.83%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	26.28%	Oper. Margin	-	ATR (14)	0.61	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	28.05	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.59	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	28.05	EPS Q/Q	-205.49%	SMA20	-0.14%	Beta	-0.47	Target Price	19.62
Payout	-	Debt/Eq	0.36	Sales Q/Q	-	SMA50	17.19%	Rel Volume	0.89	Prev Close	8.67
Employees	55	LT Debt/Eq	0.35	Earnings	May 14 BMO	SMA200	43.49%	Avg Volume	1.80M	Price	8.35
IPO	Jul 27, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	52.67% -	Trades		Volume	1,590,416	Change	-3.69%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-20-26	Initiated	Cantor Fitzgerald	Overweight
Oct-28-25	Initiated	Stephens	Overweight	$15
Sep-03-25	Downgrade	BofA Securities	Buy → Neutral	$7
Jun-30-25	Resumed	H.C. Wainwright	Buy	$23
Feb-20-25	Initiated	Citigroup	Buy	$25
Feb-19-25	Initiated	Canaccord Genuity	Buy	$20
Feb-07-25	Initiated	BofA Securities	Buy	$15
Dec-02-22	Initiated	H.C. Wainwright	Buy	$11
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$18
Aug-23-21	Initiated	UBS	Buy	$9
Aug-23-21	Initiated	Jefferies	Buy	$22
Aug-23-21	Initiated	Credit Suisse	Outperform	$15

Show Previous Ratings

Jun-05-26 06:23AM	CADL Stock Heads For Best Week In A Month Heres Why Retail Is Bullish (Stocktwits) -8.20%
Jun-02-26 08:05AM	Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer (GlobeNewswire)
Jun-01-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-26 04:05PM	Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting (GlobeNewswire) -9.92%
May-14-26 08:05AM	Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:05AM	Loading…
May-13-26 08:05AM	Candel Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-04-26 08:05AM	Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting (GlobeNewswire) +16.38%
May-01-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-26 08:36AM	Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch (Proactive)
08:05AM	Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer (GlobeNewswire)
07:51AM	Nasdaq falls back after mixed earnings, Fed holds but signals dissent (Proactive)
Apr-02-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-17-26 02:53PM	Nasdaq rises with IBM, Goldman Sachs leading, as Iran strikes continue (Proactive)
10:35AM	Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 (Proactive)
08:05AM	Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors (GlobeNewswire)
09:33AM	Loading…
Mar-12-26 09:33AM	Candel Therapeutics strengthens balance sheet as lead cancer therapy advances (Proactive)
08:05AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-09-26 08:05AM	Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting (GlobeNewswire)
Mar-02-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-24-26 08:05AM	Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston (GlobeNewswire)
Feb-20-26 08:40AM	Candel Therapeutics prices $100M public offering (Proactive) -14.20%
05:55AM	Why Is Candel Therapeutics Stock Falling Friday? (Benzinga)
04:57AM	Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers-Grail, Candel Therapeutics, Copart In Focus (Benzinga)
Feb-19-26 09:40PM	Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire)
04:36PM	Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering (Proactive)
04:05PM	Candel Therapeutics Announces Proposed $100 Million Public Offering (GlobeNewswire)
04:01PM	Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer (GlobeNewswire)
Feb-11-26 08:05AM	Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit (GlobeNewswire)
Feb-02-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-20-26 09:12AM	New Strong Sell Stocks for January 20th (Zacks) -7.50%
04:05PM	Loading…
Nov-17-25 04:05PM	Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 (GlobeNewswire)
Nov-13-25 08:25AM	Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.30%
Nov-04-25 09:00AM	Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors (GlobeNewswire)
Nov-03-25 08:05AM	Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-16-25 08:05AM	Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board (GlobeNewswire) -9.29%
Oct-15-25 08:31AM	Candel Therapeutics announces interim data from phase 1b CAN-3110 trial (TipRanks)
Oct-14-25 08:10AM	Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer (PR Newswire) -10.74%
08:10AM	Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. (GlobeNewswire)
08:05AM	Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine (GlobeNewswire)
Oct-03-25 09:05AM	Candel Therapeutics to Present at the SITC 2025 Annual Meeting (GlobeNewswire)
Sep-29-25 08:05AM	Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
Sep-17-25 08:05AM	Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
Sep-02-25 08:05AM	Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board (GlobeNewswire)
Aug-28-25 08:05AM	Candel Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-14-25 08:05AM	Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.63%
Jul-30-25 08:05AM	Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-25-25 08:23AM	Candel Therapeutics' CAN-2409 gains EMA orphan designation (Pharmaceutical Business Review)
Jul-24-25 08:05AM	Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jul-09-25 08:05AM	Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution (GlobeNewswire) +16.22%
Jun-25-25 12:00PM	Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jun-24-25 09:05AM	Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock (GlobeNewswire)
Jun-23-25 08:05AM	Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer (GlobeNewswire)
Jun-06-25 08:05AM	Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire) +8.83%
Jun-02-25 09:55AM	Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? (Zacks)
May-29-25 11:41PM	Candel Therapeutics, Inc. (CADL)'s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer (Insider Monkey) -6.84%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
May-28-25 08:05AM	Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer (GlobeNewswire) +6.07%
May-27-25 08:05AM	Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation (GlobeNewswire)
May-23-25 01:46AM	Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 (Insider Monkey)
May-22-25 05:05PM	Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire)
May-19-25 10:00AM	Best Momentum Stocks to Buy for May 19th (Zacks) +6.54%
07:49AM	New Strong Buy Stocks for May 19th (Zacks)
May-16-25 09:55AM	Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know (Zacks)
May-13-25 08:05AM	Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +7.68%
May-06-25 08:05AM	Candel Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -7.83%
Apr-23-25 04:05PM	Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire) +5.04%
Apr-01-25 08:01AM	Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients (GlobeNewswire)
Mar-27-25 03:46PM	Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients (Benzinga) -7.33%
Mar-26-25 04:05PM	Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment (GlobeNewswire) -8.76%
Mar-25-25 09:55AM	Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now (Zacks) -5.08%
Mar-20-25 08:00AM	Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 (GlobeNewswire) -7.30%
Mar-18-25 08:00AM	Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board (GlobeNewswire)
Mar-13-25 04:15PM	Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.20%
Feb-25-25 01:58PM	Candel Therapeutics stock drops despite OS improvement in PDAC trial (Clinical Trials Arena) -23.49%
08:00AM	Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Jan-13-25 08:00AM	Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 (GlobeNewswire) -5.01%
Jan-09-25 01:44AM	After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win (Pharma Voice)
Dec-19-24 01:44PM	Hedge Fund and Insider Trading News: Simon Sadler, Stanley Druckenmiller, Warren Buffett, Caxton Associates, Millennium Management, Saba Capital, Candel Therapeutics Inc (CADL), NVIDIA Corp (NVDA), and More (Insider Monkey) +52.53%
Dec-16-24 04:01PM	Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.81% +7.23%
Dec-12-24 11:00PM	Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire) +26.45% -31.12%
04:51PM	Candel Therapeutics Announces $80 Million Proposed Public Offering (GlobeNewswire)
Dec-11-24 04:09PM	Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily) +68.11%
01:07PM	Candel Therapeutics Prostate Cancer Therapy Shows Promise (Exec Edge)
11:54AM	Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily)
10:32AM	Candel Therapeutics stock up 172% after Phase III prostate cancer success (Clinical Trials Arena)
09:19AM	Candel Therapeutics Stock Surges Over 100% - Here's Why (Benzinga)
07:00AM	Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival (GlobeNewswire)
Nov-14-24 08:00AM	Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-07-24 08:00AM	Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 (GlobeNewswire)
Nov-05-24 09:00AM	Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma (GlobeNewswire)
Oct-29-24 08:59AM	Candel Therapeutics Advances in Cancer Treatment Trials (TipRanks)
Oct-28-24 08:00AM	Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) (GlobeNewswire)
Oct-04-24 09:00AM	Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting (GlobeNewswire)
Sep-04-24 08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire)
Sep-03-24 08:00AM	Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.52%
Aug-13-24 08:00AM	Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Jun-18-24 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -6.93%
Jun-14-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments (News Direct)
07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace)

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

M.D.Dr. Paul-Peter Tak FOCIS

Senior VPMr. Charles Schoch

Ph.D.Dr. Francesca Barone M.D.

Chief Technical & Development OfficerDr. Seshu Tyagarajan Ph.D.

Chief People OfficerMs. Ileen B. Winick

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Paul B	Director	Feb 23 '26	Buy	5.45	550,458	2,999,996	2,763,527	Feb 26 07:38 PM
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Option Exercise	1.29	937	1,209	53,430	Jul 30 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Sale	6.98	937	6,540	52,493	Jul 30 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Option Exercise	1.29	781	1,007	53,274	Jul 02 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Sale	5.04	781	3,936	52,493	Jul 02 04:30 PM
WILLIAM GARRETT NICHOLS	Officer	Jun 30 '25	Proposed Sale	4.90	3,593	17,606		Jun 30 04:19 PM

Open in Screener

VRCA

Verrica Pharmaceuticals Inc

Jun 10 • 04:00PM ET

5.75

-0.37 -6.05 %

Healthcare • Biotechnology • USA • Micro • NASD

VRCA Verrica Pharmaceuticals Inc daily Stock Chart

Peers: AGEN CNTB GALT IMUX KZIA SPRO MOLN HURA ORMP PLX

| Held by: VXF VTI DFAS DFMC DCOR DFAC AVTM

Index	-	P/E	-	EPS (ttm)	-1.03	Insider Own	48.75%	Shs Outstand	17.18M	Perf Week	-2.04%
Market Cap	98.77M	Forward P/E	-	EPS next Y	-0.92	Insider Trans	0.00%	Shs Float	8.80M	Perf Month	-22.30%
Enterprise Value	79.61M	PEG	-	EPS next Q	-0.41	Inst Own	27.81%	Short Float	4.31%	Perf Quarter	-8.15%
Income	-17.83M	P/S	2.66	EPS this Y	5.95%	Inst Trans	-5.51%	Short Ratio	4.04	Perf Half Y	-29.10%
Sales	37.16M	P/B	6.15	EPS next Y	41.61%	ROA	-44.03%	Short Interest	0.38M	Perf YTD	-30.81%
Book/sh	0.93	P/C	4.79	EPS next 5Y	-	ROE	-240.35%	52W High	9.82 -41.45%	Perf Year	-4.33%
Cash/sh	1.20	P/FCF	-	EPS past 3/5Y	38.35% 37.12%	ROIC	-106.40%	52W Low	3.28 75.30%	Perf 3Y	-90.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	57.93% -	Gross Margin	89.52%	Volatility	10.10% 9.54%	Perf 5Y	-94.55%
Dividend TTM	-	EV/Sales	2.14	EPS Y/Y TTM	91.39%	Oper. Margin	-36.39%	ATR (14)	0.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.90	Sales Y/Y TTM	417.63%	Profit Margin	-47.97%	RSI (14)	42.72	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.02	EPS Q/Q	55.76%	SMA20	-5.36%	Beta	1.46	Target Price	15.60
Payout	-	Debt/Eq	0.09	Sales Q/Q	46.06%	SMA50	-8.46%	Rel Volume	0.55	Prev Close	6.12
Employees	76	LT Debt/Eq	0.04	Earnings	May 12 AMC	SMA200	-2.58%	Avg Volume	93.77K	Price	5.75
IPO	Jun 15, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	0.84% 11.27%	Trades		Volume	51,958	Change	-6.05%

Date	Action	Analyst	Rating Change	Price Target Change
May-26-26	Resumed	H.C. Wainwright	Buy	$12
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

May-28-26 08:05AM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-26 08:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
01:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-12-26 04:01PM	Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 08:35AM	NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA (Exec Edge) +17.74%
04:05PM	Loading…
May-05-26 04:05PM	Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting (GlobeNewswire) +12.58%
08:00AM	Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 (GlobeNewswire)
Apr-09-26 04:05PM	Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting (GlobeNewswire) -12.35%
Apr-06-26 08:00AM	Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +9.32%
Mar-11-26 03:01PM	Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
08:00AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-05-26 08:00AM	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 (GlobeNewswire)
Feb-23-26 08:00AM	Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 08:00AM	Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer (GlobeNewswire)
Feb-09-26 08:00AM	Verrica Pharmaceuticals Announces Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical (GlobeNewswire)
12:00PM	Loading…
Feb-02-26 12:00PM	Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why (Zacks) +5.97%
05:59AM	New Strong Buy Stocks for February 2nd (Zacks)
Jan-12-26 09:55AM	How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% (Zacks)
Jan-07-26 08:00AM	Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts (GlobeNewswire)
Nov-24-25 08:00AM	Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway (GlobeNewswire) +12.11%
Nov-17-25 04:00PM	Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com) -5.09%
Nov-14-25 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-10-25 08:00AM	Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +11.85%
Oct-24-25 11:00AM	Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 04:05PM	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union (GlobeNewswire) +7.95% -9.82%
Oct-07-25 04:05PM	Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-19-25 08:00AM	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum (GlobeNewswire) +8.66%
Sep-02-25 07:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 03:12AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Aug-12-25 05:20PM	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Loading…
04:01PM	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 09:42AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.51%
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.20%
07:00AM	Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 (GlobeNewswire)
Jul-09-25 07:00AM	Verrica Pharmaceuticals Reports Strong Growth in YCANTH Dispensed Applicator Units in 2Q 2025 (GlobeNewswire)
Jul-01-25 07:00AM	Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire) +13.37%
May-28-25 08:00AM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire) -5.78%
May-14-25 08:10AM	Q1 2025 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ... (GuruFocus.com)
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.63%
04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +15.07%
09:52AM	Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result (GuruFocus.com)
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.97%
May-07-25 08:00AM	Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 (GlobeNewswire) -9.20%
May-02-25 07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates (Zacks)
Apr-30-25 08:00AM	Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York (GlobeNewswire)
Apr-07-25 08:00AM	Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH Dispensed Applicator Units in First Quarter 2025 (GlobeNewswire) +21.75%
Apr-02-25 04:05PM	Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors (GlobeNewswire)
Apr-01-25 09:55AM	Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-31-25 08:00AM	Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-25 07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.75%
Mar-12-25 01:48PM	Q4 2024 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.56%
03:08AM	Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Mar-11-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 07:00AM	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 (GlobeNewswire)
Feb-27-25 10:00AM	Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -16.89%
Feb-25-25 04:05PM	Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston (GlobeNewswire)
Jan-21-25 07:00AM	Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference (GlobeNewswire) +5.12%
Dec-20-24 07:00AM	Verrica Provides Business and Operational Update (GlobeNewswire)
Dec-09-24 04:15PM	Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.94% -7.84%
Dec-06-24 08:00AM	Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-21-24 07:30AM	Verrica Announces Pricing of $42.0 Million Public Offering (GlobeNewswire) +11.56%
Nov-20-24 04:05PM	Verrica Announces Proposed Public Offering (GlobeNewswire)
Nov-04-24 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition (GlobeNewswire) -6.54% -44.23%
Oct-24-24 07:00AM	Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-09-24 06:21PM	Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
Oct-02-24 07:30AM	Verrica Pharmaceuticals Announces Restructuring of Commercial Organization (GlobeNewswire) -18.98%
Sep-29-24 08:02AM	Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:27AM	Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? (Insider Monkey) -5.68%
Sep-20-24 05:21AM	Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) (Newsfile) -6.70%
Sep-04-24 07:30AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York (GlobeNewswire) +5.50%
Aug-15-24 07:32AM	Verrica stock drops after half patients tumours gone in skin cancer trial (Clinical Trials Arena) -6.73%
Aug-14-24 09:52AM	Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -40.80%
08:55AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma (GlobeNewswire)
Aug-06-24 07:30AM	Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 (GlobeNewswire) -5.45%
Jul-15-24 11:57AM	7 Short-Squeeze Stocks That Could Beat Down the Bears (InvestorPlace)
Jul-01-24 07:30AM	Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. (GlobeNewswire) +9.05%
May-30-24 04:30PM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)
08:40AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Verrica Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-08-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-06-24 06:35AM	Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Ph.D.Dr. Jayson M. Rieger M.B.A.

Interim Chief Financial OfficerMr. John J. Kirby CPA

Chief Medical OfficerDr. Noah L. Rosenberg M.D.

COOMr. David Zawitz

Executive Vice President of Technical OperationsMr. Eugene Scavola

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenberg Noah L.	CMO	Nov 25 '25	Buy	4.24	2,357	10,000	2,357	Nov 25 07:00 PM
Kirby John J.	Interim CFO	Nov 25 '25	Buy	4.24	3,536	15,001	8,962	Nov 25 07:00 PM
Zawitz David	Chief Operating Officer	Nov 25 '25	Buy	4.24	10,000	42,425	21,000	Nov 25 07:00 PM
Rieger Jayson	CEO and President	Nov 25 '25	Buy	4.24	94,311	400,114	182,593	Nov 25 07:00 PM
Manning Paul B	Director	Nov 25 '25	Buy	4.24	2,750,762	11,670,108	3,348,372	Nov 25 07:00 PM
Manning Paul B	Director	Nov 25 '25	Buy	4.24	1,375,380	5,835,050	3,958,189	Nov 25 07:00 PM

Open in Screener

TSHA

Taysha Gene Therapies Inc

Jun 10 • 04:00PM ET

5.40

+0.04 0.75 %

Healthcare • Biotechnology • USA • Small • NASD

TSHA Taysha Gene Therapies Inc daily Stock Chart

Peers: BEAM NTLA CRSP EDIT BMRN KRYS RYTM KYMR NUVL INCY

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA FESM KOMP

Index	RUT	P/E	-	EPS (ttm)	-0.40	Insider Own	17.18%	Shs Outstand	287.28M	Perf Week	-2.70%
Market Cap	1.55B	Forward P/E	-	EPS next Y	-0.46	Insider Trans	-1.59%	Shs Float	237.99M	Perf Month	-20.82%
Enterprise Value	1.34B	PEG	-	EPS next Q	-0.12	Inst Own	90.88%	Short Float	15.13%	Perf Quarter	19.60%
Income	-129.88M	P/S	207.73	EPS this Y	-39.82%	Inst Trans	-2.76%	Short Ratio	13.18	Perf Half Y	-0.92%
Sales	7.47M	P/B	7.32	EPS next Y	4.10%	ROA	-59.21%	Short Interest	36.01M	Perf YTD	-1.82%
Book/sh	0.74	P/C	5.60	EPS next 5Y	8.63%	ROE	-97.28%	52W High	7.30 -26.03%	Perf Year	106.90%
Cash/sh	0.96	P/FCF	-	EPS past 3/5Y	55.14% 36.86%	ROIC	-46.61%	52W Low	2.25 140.00%	Perf 3Y	527.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	57.49% -	Gross Margin	84.51%	Volatility	7.40% 6.64%	Perf 5Y	-78.05%
Dividend TTM	-	EV/Sales	179.86	EPS Y/Y TTM	-11.04%	Oper. Margin	-1774.37%	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.03	Sales Y/Y TTM	3.42%	Profit Margin	-1738.40%	RSI (14)	42.39	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	14.03	EPS Q/Q	-44.81%	SMA20	-5.26%	Beta	1.21	Target Price	12.23
Payout	-	Debt/Eq	0.32	Sales Q/Q	-100.00%	SMA50	-6.64%	Rel Volume	0.80	Prev Close	5.36
Employees	99	LT Debt/Eq	0.31	Earnings	May 06 BMO	SMA200	12.68%	Avg Volume	2.73M	Price	5.40
IPO	Sep 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.10% -100.00%	Trades		Volume	2,179,713	Change	0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Raymond James	Strong Buy	$13
Jul-11-25	Initiated	BofA Securities	Buy	$8
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$5
Apr-09-24	Initiated	Piper Sandler	Overweight	$9
Feb-01-23	Downgrade	Jefferies	Buy → Hold	$14 → $1.50
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$23 → $3
Nov-09-22	Downgrade	Goldman	Buy → Neutral	$16 → $3
Mar-09-22	Initiated	Robert W. Baird	Outperform	$26
Mar-01-22	Initiated	Wells Fargo	Overweight	$25
Feb-18-22	Initiated	SMBC Nikko	Outperform	$25
Dec-16-21	Initiated	Guggenheim	Buy	$28
Jul-16-21	Initiated	Needham	Buy	$45
Jun-24-21	Initiated	Truist	Buy	$60
Jun-15-21	Initiated	BTIG Research	Buy	$44
Jun-09-21	Initiated	Wedbush	Outperform	$31
Jun-08-21	Initiated	JMP Securities	Mkt Outperform	$40
May-19-21	Initiated	Cantor Fitzgerald	Overweight	$44
May-11-21	Resumed	Jefferies	Buy	$34 → $45
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform	$42

Show Previous Ratings

Jun-05-26 08:01AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.62%
May-07-26 08:30AM	Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary (Moby)
May-06-26 08:00AM	Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-26 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-26 08:00AM	Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 (GlobeNewswire)
05:21PM	Loading…
Apr-27-26 05:21PM	Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting (GlobeNewswire)
Apr-03-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-19-26 03:03PM	Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
12:48PM	Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary (Moby)
08:00AM	Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-26 09:17AM	Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-12-26 08:00AM	Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 (GlobeNewswire)
Mar-06-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 09:37AM	Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress (Insider Monkey)
01:48PM	Loading…
Jan-29-26 01:48PM	Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) (Insider Monkey)
Jan-14-26 02:13PM	Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects (Insider Monkey)
Jan-06-26 08:00AM	Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome (GlobeNewswire) +7.57%
Dec-21-25 07:31AM	Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program (Insider Monkey)
Dec-05-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.92%
Nov-18-25 06:17AM	Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? (Insider Monkey)
Nov-07-25 09:34PM	Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) (Insider Monkey)
Nov-04-25 04:09PM	Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -5.62%
07:00AM	Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-25 07:41AM	What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings (GuruFocus.com) -10.08%
Oct-28-25 08:00AM	Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 (GlobeNewswire)
Oct-26-25 06:16AM	Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum (Insider Monkey)
Oct-17-25 06:00AM	I-Mab morphs into hub-and-spoke biotech; Astellas passes on Taysha gene therapy (BioPharma Dive) -7.09%
03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Oct-16-25 04:01PM	Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome (GlobeNewswire)
08:00AM	Loading…
Oct-09-25 08:00AM	Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting (GlobeNewswire)
Oct-03-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Oct-02-25 08:00AM	Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome (GlobeNewswire) +53.46%
Sep-05-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 11:56PM	Piper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9 (Insider Monkey)
Aug-13-25 03:07AM	Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... (GuruFocus.com)
Aug-12-25 03:00PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.43%
08:01AM	Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:27AM	Earnings To Watch: Taysha Gene Therapies Inc (TSHA) Reports Q2 2025 Result (GuruFocus.com)
Aug-07-25 05:15PM	Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-05-25 04:05PM	Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-04-25 10:01AM	Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) (Insider Monkey)
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know (Zacks)
Aug-01-25 05:06PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:47AM	BofA Securities Affirms 'Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects (Insider Monkey)
Jul-22-25 06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-16-25 12:00PM	Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jul-03-25 01:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 03:51PM	Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT (Insider Monkey)
Jun-18-25 09:16AM	Craig-Hallum bullish on Neurogene, initiates with a Buy (TipRanks)
Jun-06-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 05:17PM	Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program (GlobeNewswire)
May-29-25 12:12AM	Taysha Gene Therapies, Inc. (TSHA)'s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+ (Insider Monkey) +12.70%
May-28-25 10:40PM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.33%
04:02PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102 (GlobeNewswire)
May-16-25 03:19AM	Q1 2025 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents) +5.47%
03:09AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ... (GuruFocus.com)
May-15-25 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.02%
08:00AM	Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-25 09:40AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.53%
04:05PM	Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 (GlobeNewswire)
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -18.70% -5.00%
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
May-02-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha) +16.94%
Apr-15-25 04:04PM	Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity (Seeking Alpha) -7.09%
Apr-04-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.99%
Mar-19-25 04:31PM	Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? (InsiderMonkey) +5.17% -7.10%
Mar-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 01:04AM	Q4 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 09:15AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-25 10:57AM	Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-25 08:00AM	Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 (GlobeNewswire)
Feb-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.42%
Jan-03-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-24 12:51PM	Q3 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... (GuruFocus.com)
Nov-13-24 05:15PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.53%
04:01PM	Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 08:00AM	Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 (GlobeNewswire) +7.87%
Nov-01-24 04:30PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.47% -12.42%
Oct-22-24 08:00AM	Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress (GlobeNewswire)
Oct-16-24 03:42PM	Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-14-24 12:00PM	Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-04-24 08:01AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-24 04:55AM	Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-26-24 08:00AM	Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress (GlobeNewswire)
Sep-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:01AM	Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-24 08:00AM	Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

CEO & ChairmanMr. Sean P. Nolan

PresidentDr. Sukumar Nagendran M.D.

M.B.A.Mr. Kamran Alam CPA

Director of Corporate Communications & Investor RelationsHayleigh Collins

Chief of Staff & Technical Operations OfficerMr. Frederick Porter Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Option Exercise	1.71	19,021	32,526	1,336,410	Apr 13 04:33 PM
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Sale	4.46	200,000	892,000	1,136,410	Apr 13 04:33 PM
Nagendran Sukumar	Officer	Apr 10 '26	Proposed Sale	4.63	200,000	926,000		Apr 10 04:11 PM
Rumana Haque-Ahmed	Officer	Feb 27 '26	Proposed Sale	4.57	2,405	10,991		Feb 27 04:07 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	4.52	1,655	7,481	1,442,131	Feb 06 04:30 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Feb 04 '26	Proposed Sale	4.72	901	4,253		Feb 04 06:44 PM
Fred Porter	Affiliate-Chief of Staff &	Feb 04 '26	Proposed Sale	4.72	889	4,196		Feb 04 06:42 PM
Sean McAuliffe	Affiliate - Chief Business Off	Feb 04 '26	Proposed Sale	4.72	914	4,314		Feb 04 06:41 PM
Rumana Haque-Ahmed	Officer	Feb 04 '26	Proposed Sale	4.72	697	3,290		Feb 04 06:39 PM
Kamran Alam	Officer	Feb 04 '26	Proposed Sale	4.72	1,655	7,812		Feb 04 06:38 PM
Nagendran Sukumar	President and Head of R&D	Jan 23 '26	Sale	4.75	89,132	423,377	1,344,307	Jan 27 04:05 PM
Nagendran Sukumar	President and Head of R&D	Jan 26 '26	Sale	4.61	26,918	124,092	1,317,389	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 23 '26	Sale	4.75	136,789	649,748	2,949,569	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 26 '26	Sale	4.61	41,312	190,448	2,908,257	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 23 '26	Sale	4.75	78,968	375,098	1,467,635	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	4.61	23,849	109,944	1,443,786	Jan 27 04:05 PM
Sean P. Nolan	Officer	Jan 23 '26	Proposed Sale	5.09	168,078	855,517		Jan 23 08:07 PM
Sukumar Nagendran	Officer	Jan 23 '26	Proposed Sale	5.09	113,824	579,364		Jan 23 08:05 PM
Rumana Haque-Ahmed	Officer	Jan 23 '26	Proposed Sale	5.09	30,052	152,965		Jan 23 08:04 PM
Fred Porter	Affiliate-Chief of Staff &	Jan 23 '26	Proposed Sale	5.09	54,916	279,522		Jan 23 08:02 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Jan 23 '26	Proposed Sale	5.09	32,077	163,272		Jan 23 08:01 PM
Sean McAuliffe	Affiliate - Chief Business Off	Jan 23 '26	Proposed Sale	5.09	46,064	234,466		Jan 23 07:59 PM
Kamran Alam	Officer	Jan 23 '26	Proposed Sale	5.09	100,846	513,306		Jan 23 07:58 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Option Exercise	1.15	200,000	229,440	1,206,439	Jan 14 04:45 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Sale	4.71	200,000	942,000	1,006,439	Jan 14 04:45 PM
Nagendran Sukumar	Officer	Jan 12 '26	Proposed Sale	4.98	200,000	996,000		Jan 12 04:19 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Option Exercise	1.71	260,047	444,680	1,266,486	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Option Exercise	1.07	110,125	117,363	1,116,564	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Sale	4.51	260,047	1,172,812	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Sale	4.75	110,125	523,094	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	Officer	Nov 28 '25	Proposed Sale	4.86	370,172	1,799,036		Nov 28 01:07 PM
Rumana Haque-Ahmed	Officer	Sep 22 '25	Proposed Sale	2.83	10,770	30,479		Sep 22 07:18 PM
Nagendran Sukumar	President and Head of R&D	Sep 10 '25	Option Exercise	0.70	41,150	28,760	1,206,439	Sep 12 04:15 PM
Nagendran Sukumar	President and Head of R&D	Sep 10 '25	Sale	3.23	200,000	646,000	1,006,439	Sep 12 04:15 PM
Nagendran Sukumar	Officer	Sep 10 '25	Proposed Sale	3.26	200,000	652,000		Sep 10 04:28 PM
Nagendran Sukumar	President and Head of R&D	Aug 21 '25	Sale	2.85	57,054	162,604	1,165,289	Aug 22 04:15 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Aug 21 '25	Sale	2.85	54,491	155,299	1,187,603	Aug 22 04:15 PM
Kamran Alam	Officer	Aug 21 '25	Proposed Sale	2.87	54,491	156,389		Aug 21 09:12 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Aug 21 '25	Proposed Sale	2.87	19,604	56,263		Aug 21 09:11 PM
Sukumar Nagendran	Officer	Aug 21 '25	Proposed Sale	2.87	57,054	163,745		Aug 21 09:10 PM
Sean McAuliffe	Affiliate - Chief Business Off	Aug 21 '25	Proposed Sale	2.87	27,590	79,183		Aug 21 09:09 PM
Fred Porter	Affiliate-Chief of Staff &	Aug 21 '25	Proposed Sale	2.87	50,451	144,794		Aug 21 09:08 PM

LQDA

Liquidia Corp

CADL

Candel Therapeutics Inc

VRCA

Verrica Pharmaceuticals Inc

TSHA

Taysha Gene Therapies Inc

Upgrade your Finviz experience